A novel anti-TNF injection treatment for Dupuytren’s disease, developed at the University of Oxford in the UK, was the subject of a randomized, double-blind, placebo-controlled Phase 2b trial. Final efficacy data from the study has just been released. The study, “Anti-tumor necrosis factor therapy for early-stage Dupuytren’s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled […]

Descartes-08, Cartesian Therapeutics’ investigational CAR T-cell therapy, appears generally safe and markedly lessened symptom severity in the first five patients with generalized myasthenia gravis (gMG) enrolled in a Phase 1b/2a clinical trial. “I am very encouraged by the interim analysis findings,” as the therapy “appears safe and well tolerated, and the extent of clinical improvement seen in our […]

From last night’s happy hour drinks to this morning’s greasy breakfast burrito and ibuprofen, the liver has seen it all. As both factory and filter, the liver is a jack of all trades. It removes harmful toxins from the blood, creates bile to carry away waste, metabolizes drugs, stores iron and other vitamins, and even […]